Considerations for safe implementation

These guidelines are the results of an expert panel discussion at GOSH/UCL, including clinicians and researchers who have shared their experiences from their involvement with AAV-gene therapy trials. They address issues such as adverse events reported so far, immunosuppressive regimens, and next steps. 

GOSH - Consideration for Safe Implementation

We have placed cookies on your computer to help make this website better. For more information please click here

By continuing to use this site or closing this panel, we'll assume you're OK to continue. You can view our full privacy policy here